7 research outputs found
Automated office blood pressure measurements in primary care are misleading in more than one third of treated hypertensives: The VALENTINE-Greece Home Blood Pressure Monitoring study
Abstract Background This study assessed the diagnostic reliability of automated office blood pressure (OBP) measurements in treated hypertensive patients in primary care by evaluating the prevalence of white coat hypertension (WCH) and masked uncontrolled hypertension (MUCH) phenomena. Methods Primary care physicians, nationwide in Greece, assessed consecutive hypertensive patients on stable treatment using OBP (1 visit, triplicate measurements) and home blood pressure (HBP) measurements (7 days, duplicate morning and evening measurements). All measurements were performed using validated automated devices with bluetooth capacity (Omron M7 Intelli-IT). Uncontrolled OBP was defined as â„140/90 mmHg, and uncontrolled HBP was defined as â„135/85 mmHg. Results A total of 790 patients recruited by 135 doctors were analyzed (age: 64.5 ± 14.4 years, diabetics: 21.4%, smokers: 20.6%, and average number of antihypertensive drugs: 1.6 ± 0.8). OBP (137.5 ± 9.4/84.3 ± 7.7 mmHg, systolic/diastolic) was higher than HBP (130.6 ± 11.2/79.9 ± 8 mmHg; difference 6.9 ± 11.6/4.4 ± 7.6 mmHg, p Conclusions In primary care, automated OBP measurements are misleading in approximately 40% of treated hypertensive patients. HBP monitoring is mandatory to avoid overtreatment of subjects with WCH phenomenon and prevent undertreatment and subsequent excess cardiovascular disease in MUCH
Powder Compaction: Compression Properties of Cellulose Ethers
Effective development of matrix tablets requires a comprehensive understanding of different raw material attributes and their impact on process parameters. Cellulose ethers (CE) are the most commonly used pharmaceutical excipients in the fabrication of hydrophilic matrices. The innate good compression and binding properties of CE enable matrices to be prepared using economical direct compression (DC) techniques. However, DC is sensitive to raw material attributes, thus, impacting the compaction process. This article critically reviews prior knowledge on the mechanism of powder compaction and the compression properties of cellulose ethers, giving timely insight into new developments in this field
Automated office blood pressure measurements in primary care are misleading in more than one third of treated hypertensives: The VALENTINE-Greece Home Blood Pressure Monitoring study
Background: This study assessed the diagnostic reliability of automated office blood pressure (OBP) measurements in treated hypertensive patients in primary care by evaluating the prevalence of white coat hypertension (WCH) and masked uncontrolled hypertension (MUCH) phenomena. Methods: Primary care physicians, nationwide in Greece, assessed consecutive hypertensive patients on stable treatment using OBP (1 visit, triplicate measurements) and home blood pressure (HBP) measurements (7 days, duplicate morning and evening measurements). All measurements were performed using validated automated devices with bluetooth capacity (Omron M7 Intelli-IT). Uncontrolled OBP was defined as â„140/90 mmHg, and uncontrolled HBP was defined as â„135/85 mmHg. Results: A total of 790 patients recruited by 135 doctors were analyzed (age: 64.5 ± 14.4 years, diabetics: 21.4%, smokers: 20.6%, and average number of antihypertensive drugs: 1.6 ± 0.8). OBP (137.5 ± 9.4/84.3 ± 7.7 mmHg, systolic/diastolic) was higher than HBP (130.6 ± 11.2/79.9 ± 8 mmHg; difference 6.9 ± 11.6/4.4 ± 7.6 mmHg, p < 0.001). WCH phenomenon (high OBP with low HBP) was observed in 22.7% of the patients, MUCH (low OBP with high HBP) in 15.8%, uncontrolled hypertension (high OBP with high HBP) in 29.9%, and controlled hypertension (low OBP with low HBP) in 31.6%. In multivariate logistic regression analysis, WCH was determined by stage-1 systolic hypertension (odds ratio [OR] 8.6, 95% confidence intervals [CI] 5.7, 13.1) and female gender (OR 1.6, 95% CI 1.1, 2.4), whereas MUCH was determined by high-normal systolic OBP (OR 6.2, 95% CI 3.8, 10.1) and male gender (OR 2.0, 95% CI 1.2, 3.1). Conclusions: In primary care, automated OBP measurements are misleading in approximately 40% of treated hypertensive patients. HBP monitoring is mandatory to avoid overtreatment of subjects with WCH phenomenon and prevent undertreatment and subsequent excess cardiovascular disease in MUCH. © 2019 Hellenic Society of Cardiolog
Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome - Results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study
Background: Angiotensin-converting enzyme inhibitors
reduce mortality and remodeling after myocardial
infarction in patients with left ventricular dysfunction.
Methods: Perindopril and Remodeling in Elderly With
Acute Myocardial Infarction (PREAMI), a doubleblind,
randomized, parallel-group, multicenter, placebocontrolled
study, determined whether similar benefits occur
in elderly postinfarction patients with preserved left
ventricular function. A total of 1252 patients 65 years or
older with a left ventricular ejection fraction of 40% or
higher and recent acute myocardial infarction were randomized
to receive perindopril erbumine or placebo (8
mg/d) for 12 months. The combined primary end point
was death, hospitalization for heart failure, or left ventricular
remodeling. Secondary end points included cardiovascular
death, hospitalization for reinfarction or angina,
and revascularization.
Results: The primary end point occurred in 181 patients
(35%) taking perindopril and 290 patients (57%)
taking placebo, with a significant absolute risk reduction
of 0.22 (95% confidence interval, 0.16 to 0.28;
P.001). A total of 126 patients (28%) and 226 patients
(51%) in the perindopril and placebo groups, respectively,
experienced remodeling. The mean increase in left
ventricle end-diastolic volume was 0.7 mL with perindopril
compared with 4.0 mL with placebo (P.001). In
the perindopril group, 40 deaths (6%) and 22 hospitalizations
(4%) for heart failure occurred, whereas 37 deaths
(6%) and 30 hospitalizations (5%) occurred in the placebo
group. Treatment did not affect death, whereas the
hospitalization rate for heart failure was slightly reduced
(absolute risk reduction, 0.01; 95% confidence interval,
â0.01 to 0.02). No treatment effect on other secondary
end points was detected.
Conclusion:Wefound that 1-year treatment with 8mg/d
of perindopril reduces progressive left ventricular remodeling
that can occur even in the presence of small
infarct size, but it was not associated with better clinical
outcomes
Genome-wide identification of the TIFY gene family in three cultivated Gossypium species and the expression of JAZ genes
PREAMI: Perindopril and remodelling in elderly with acute myocardial infarction: Study rationale and design
PREAMI: Perindopril and remodelling in elderly with acute myocardial infarction: Study rationale and design
Angiotensin-converting enzyme (ACE) inhibitors reduce mortality, the development of remodeling, left ventricular (LV) dysfunction, and ischemic events, both when administered alone as long-term treatment in patients with impaired LV function and/or heart failure (HF) and as short-term treatment, early after acute myocardial infarction (AMI) and/or HF. The few data available on the use of ACE inhibitors in the elderly after AMI are conflicting. Nothing is known about the effects of ACE inhibitors in elderly postinfarction patients with preserved LV function: these patients have a remarkable medium- to long-term mortality and HF incidence after infarction. The aim of this study is to evaluate, in patients with AMI aged â„65 years, the effects of Perindopril on the combined outcome of death, hospitalization for HF, and heart remodeling, considered to be a â„8% increase in LV end-diastolic volume (LVEDV). Secondary objectives include the same factors listed in the primary end points hut considered separately. In addition, safety of the drug, ventricular remodeling, and adaptation are being evaluated. A total of 1100 patients with AMI (first episode or reinfarction), aged â„65 years, and preserved or only moderately depressed LV (LV ejection fraction â„40%), are to he enrolled and randomly assigned to treatment (8 mg for 12 months of Perindopril or placebo, in double-blind conditions). Clinical assessment is performed at fixed times, and periodic evaluations of (1) ventricular shape, dimensions, and function by quantitative 2-D echocardiography, and (2) heart rate variability and arrhythmias by ambulatory electrocardiographic monitoring are anticipated. The results and conclusions will be available by 2002 year